Bin Yu

9.5k total citations · 4 hit papers
220 papers, 7.2k citations indexed

About

Bin Yu is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Bin Yu has authored 220 papers receiving a total of 7.2k indexed citations (citations by other indexed papers that have themselves been cited), including 131 papers in Molecular Biology, 67 papers in Organic Chemistry and 37 papers in Oncology. Recurrent topics in Bin Yu's work include Epigenetics and DNA Methylation (36 papers), Histone Deacetylase Inhibitors Research (29 papers) and Cancer therapeutics and mechanisms (21 papers). Bin Yu is often cited by papers focused on Epigenetics and DNA Methylation (36 papers), Histone Deacetylase Inhibitors Research (29 papers) and Cancer therapeutics and mechanisms (21 papers). Bin Yu collaborates with scholars based in China, New Zealand and United States. Bin Yu's co-authors include Hong‐Min Liu, De‐Quan Yu, Hong‐Min Liu, Guochao Liao, Yuan Fang, Yihui Song, Kai Tang, Yi‐Chao Zheng, Ping‐Ping Qi and Shuai Wang and has published in prestigious journals such as Nature Communications, Langmuir and Oncogene.

In The Last Decade

Bin Yu

212 papers receiving 7.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Spirooxindoles: Promising scaffolds for anticancer agents

2014 747 citations Bin Yu, Hong‐Min Liu et al. European Journal of Medicinal Chemistry profile →
LSD1/KDM1A inhibitors in clinical trials: advances and prospects

2019 315 citations Guochao Liao, Bin Yu et al. profile →
Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy

2021 246 citations Kai Tang, Yahong Wu et al. profile →
Targeting epigenetic regulators to overcome drug resistance in cancers

2023 181 citations Bin Yu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bin Yu China	46	3.7k	2.8k	999	559	517	220	7.2k
Hong‐Min Liu China	42	3.5k 1.0×	1.6k 0.6×	1.2k 1.2×	283 0.5×	438 0.8×	266	5.9k
Li Zhang China	41	3.3k 0.9×	2.1k 0.7×	759 0.8×	315 0.6×	537 1.0×	221	6.4k
Tracey D. Bradshaw United Kingdom	46	2.8k 0.8×	3.4k 1.2×	903 0.9×	276 0.5×	549 1.1×	157	7.3k
Masatoshi Shibuya Japan	43	2.7k 0.7×	2.6k 0.9×	1.1k 1.1×	232 0.4×	563 1.1×	144	6.9k
Fan Yang China	41	2.1k 0.6×	1.6k 0.6×	920 0.9×	190 0.3×	490 0.9×	182	5.5k
Wenfang Xu China	37	3.0k 0.8×	1.7k 0.6×	1.6k 1.6×	154 0.3×	600 1.2×	266	5.2k
Jing‐Ping Liou Taiwan	41	3.0k 0.8×	2.3k 0.8×	1.0k 1.0×	255 0.5×	402 0.8×	182	5.4k
Silvia Schenone Italy	43	2.5k 0.7×	3.1k 1.1×	737 0.7×	270 0.5×	312 0.6×	236	5.9k
Jang‐Yang Chang Taiwan	50	3.4k 0.9×	1.6k 0.6×	1.5k 1.5×	495 0.9×	1.1k 2.1×	201	6.6k
Sushil K. Kashaw India	29	1.6k 0.4×	1.6k 0.6×	1.2k 1.2×	271 0.5×	238 0.5×	131	4.7k

Countries citing papers authored by Bin Yu

Since Specialization

Citations

This map shows the geographic impact of Bin Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bin Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bin Yu more than expected).

Fields of papers citing papers by Bin Yu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bin Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bin Yu. The network helps show where Bin Yu may publish in the future.

Co-authorship network of co-authors of Bin Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Bin Yu. A scholar is included among the top collaborators of Bin Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bin Yu. Bin Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ma, Chunhua, Yi Li, Yu Ji, Qingjie Ding, & Bin Yu. (2025). Photocatalytic Direct C3-Amidation of 2H-Indazole. The Journal of Organic Chemistry. 90(31). 11013–11019.

Zhang, Jingya, Pengxing He, Wenwen Wang, et al.. (2025). Structure-Based Design of New LSD1/EGFR^L858R/T790M Dual Inhibitors for Treating EGFR Mutant NSCLC Cancers. Journal of Medicinal Chemistry. 68(5). 5954–5972. 4 indexed citations

Tang, Kai, Shu Wang, Siqi Feng, et al.. (2024). Discovery of TK-642 as a highly potent, selective, orally bioavailable pyrazolopyrazine-based allosteric SHP2 inhibitor. Acta Pharmaceutica Sinica B. 14(8). 3624–3642. 5 indexed citations

Zhang, Chaofeng, et al.. (2023). Recent advances of LSD1/KDM1A inhibitors for disease therapy. Bioorganic Chemistry. 134. 106443–106443. 11 indexed citations

Song, Yihui, Shu Wang, Min Zhao, & Bin Yu. (2023). Development of a robust HTRF assay with USP7 full length protein expressed in E. coli prokaryotic system for the identification of USP7 inhibitors. Journal of Pharmaceutical and Biomedical Analysis. 227. 115305–115305. 1 indexed citations

Wang, Saiqi, Qiu‐Xu Teng, Shuai Wang, et al.. (2022). Preclinical studies of the triazolo[1,5-a]pyrimidine derivative WS-716 as a highly potent, specific and orally active P-glycoprotein (P-gp) inhibitor. Acta Pharmaceutica Sinica B. 12(8). 3263–3280. 24 indexed citations

Song, Yihui, Shu Wang, Min Zhao, Xinyu Yang, & Bin Yu. (2022). Strategies Targeting Protein Tyrosine Phosphatase SHP2 for Cancer Therapy. Journal of Medicinal Chemistry. 65(4). 3066–3079. 59 indexed citations

Tang, Kai, Min Zhao, Yahong Wu, et al.. (2022). Structure-based design, synthesis and biological evaluation of aminopyrazines as highly potent, selective, and cellularly active allosteric SHP2 inhibitors. European Journal of Medicinal Chemistry. 230. 114106–114106. 10 indexed citations

Song, Yihui, et al.. (2021). Annual review of lysine-specific demethylase 1 (LSD1/KDM1A) inhibitors in 2021. European Journal of Medicinal Chemistry. 228. 114042–114042. 46 indexed citations

10.

Fu, Dong‐Jun, Jun Li, & Bin Yu. (2021). Annual review of LSD1/KDM1A inhibitors in 2020. European Journal of Medicinal Chemistry. 214. 113254–113254. 27 indexed citations

11.

Wang, Shuai, Xiaohan Yuan, Saiqi Wang, et al.. (2021). FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application. European Journal of Medicinal Chemistry. 214. 113218–113218. 108 indexed citations

12.

Yuan, Shuo, Jingya Zhang, Donghui Wei, et al.. (2021). Cu(OTf)₂-Catalyzed Intramolecular Radical Cascade Reactions for the Diversity-Oriented Synthesis of Quinoline-Annulated Polyheterocyclic Frameworks. Organic Letters. 23(4). 1445–1450. 21 indexed citations

13.

Tang, Kai, Bo Wang, Bin Yu, & Hong‐Min Liu. (2021). Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and PROTAC-based degraders for cancer therapy. European Journal of Medicinal Chemistry. 227. 113967–113967. 16 indexed citations

14.

Fang, Yuan, Chao Yang, Zhiqiang Yu, et al.. (2020). Natural products as LSD1 inhibitors for cancer therapy. Acta Pharmaceutica Sinica B. 11(3). 621–631. 89 indexed citations

15.

Yuan, Shuo, Bin Yu, & Hong‐Min Liu. (2020). New drug approvals for 2019: Synthesis and clinical applications. European Journal of Medicinal Chemistry. 205. 112667–112667. 48 indexed citations

16.

Song, Yihui, Min Zhao, Yahong Wu, Bin Yu, & Hong‐Min Liu. (2020). A multifunctional cross-validation high-throughput screening protocol enabling the discovery of new SHP2 inhibitors. Acta Pharmaceutica Sinica B. 11(3). 750–762. 24 indexed citations

17.

Wang, Shuai, et al.. (2020). Discovery of new [1,2,4] Triazolo[1,5-a]Pyrimidine derivatives that Kill gastric cancer cells via the mitochondria pathway. European Journal of Medicinal Chemistry. 203. 112630–112630. 17 indexed citations

18.

Yuan, Shuo, Junbiao Chang, & Bin Yu. (2020). Construction of Biologically Important Biaryl Scaffolds through Direct C–H Bond Activation: Advances and Prospects. Topics in Current Chemistry. 378(2). 23–23. 60 indexed citations

19.

Huang, Ming-Jie, et al.. (2020). Targeting histone demethylase KDM5B for cancer treatment. European Journal of Medicinal Chemistry. 208. 112760–112760. 32 indexed citations

20.

Chen, Jinjie, et al.. (2018). Aniline-Promoted Synthesis of Isobenzofuranone Derivatives. Chinese Journal of Organic Chemistry. 38(11). 3009–3009. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact